What this is
- How it works
- How it works isn't classified yet
- Tested for
- Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
- Main trialPhase 1
- “ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease. The study will consist of different periods including screening, lymphodepletion, treatment, and follow-up”In the company’s words, NCT06375993 on ClinicalTrials.gov
Other drugs for Lupus Nephritis
- AnifrolumabAstraZeneca · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- IanalumabNovartis · Phase 3
- Mycophenolate MofetilRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- CenerimodViatris Innovation GmbH · Phase 3
Coming up2
- DecPhase 1 trial completes · ClinicalTrials.gov
- 30 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Enrolling by invitation | Dec 2026 | A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | |
| Phase 1Recruiting | 30 Mar 2027 | A Phase 1 Study of ADI-001 in Rheumatoid Arthritis | |
| Phase 1Terminated | 3 Feb 2025 | A Phase 1 Study of ADI-001 in B Cell Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026